GlassScriptPhysician profile
Jennifer Fishel
NPI 1770584567
$2,134.00
in general payments reported to CMS, 2019-2025
22 companies · $664 in 2025
The $664 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $45.56 · 2021: $46.29 · 2022: $228 · 2023: $471 · 2024: $306 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $346.89 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Alcon Vision LLC | $284.12 | 2021-2025 | Rocklatan, Rhopressa, Simbrinza |
| Harrow Eye, LLC | $241.40 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $236.79 | 2022-2025 | Tyrvaya |
| Maculogix, INC. | $152.75 | 2019-2020 | |
| Allergan, INC. | $125.00 | 2019 | |
| Coopervision INC. | $115.68 | 2019-2022 | |
| Biotissue Holdings INC. | $102.89 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.03 | 2019 | |
| Sun Pharmaceutical Industries INC. | $73.74 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $52.41 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $45.73 | 2023 | |
| Dompe US, INC. | $45.07 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $36.68 | 2022 | |
| Mallinckrodt Hospital Products INC. | $34.82 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $31.85 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $31.76 | 2023 | Tepezza |
| Amgen INC. | $25.27 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $21.19 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Merz Pharmaceuticals, LLC | $18.91 | 2025 | Xeomin |
| Shire North American Group INC | $10.99 | 2019 | |
| Visioneering Technologies, INC. | $7.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fishel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.